CA
NZ
UK
AU
IND
US
Filana Therapeutics, (NASDAQ:FLNA) the company formerly known as Cassava Sciences, is rebuilding around simufilam as a possible treatment for tuberous sclerosis complex-related epilepsy after the drug's Alzheimer's program collapsed in Phase 3. Early mouse data look encouraging, but an FDA clinical hold means no …
Curis, Inc. (NASDAQ:CRIS) has activated eleven clinical sites for its Phase 2 TakeAim CLL study and, as of July 22, 2026, had consented ten patients toward a dosing readout due by end of July. The Lexington, Massachusetts biotech also disclosed encouraging lymphoma data, but …
Elicio (NASDAQ:ELTX) Therapeutics priced a $15 million stock offering on July 1, 2026, weeks after its lead pancreatic-cancer immunotherapy missed the primary endpoint of a randomized Phase 2 trial. The Boston-based biotech says a subgroup analysis still supports a narrower Phase 3 path. Investors …
Elutia Inc. (NASDAQ:ELUT) has agreed to sell its SimpliDerm dermal matrix line to Cellution Biologics for up to $11 million, the latest step in a two-year overhaul that has shed two commercial businesses to concentrate on NXT-41x, an antibiotic-eluting biomatrix for breast reconstruction surgery. …
Femasys Inc. (NASDAQ:FEMY) has opened the final enrollment phase of its FINALE pivotal trial for FemBloc, a non-surgical permanent birth control candidate already approved in Europe, the UK and New Zealand. The milestone, announced March 10, 2026, advances a years-long U.S. regulatory path, even …
Chemomab Therapeutics Ltd. (NASDAQ:CMMB) has agreed to merge with private precision-medicine company Scipher Medicine, redirecting antibody nebokitug toward a Phase 2 rheumatoid arthritis trial guided by Scipher's PrismRA testing platform. The deal, unveiled July 8, 2026, brings a $30 million financing and a new …
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) told the thrombosis community this month that a small, statistically underpowered Phase 2 study of its 12-lipoxygenase inhibitor CAD-1005 showed a more-than-25-percentage-point drop in thrombotic events among patients with heparin-induced thrombocytopenia. With cash reserves thinning and a going-concern warning attached …
Atossa (NASDAQ:ATOS) Therapeutics used an AACR rare-cancers conference in Vancouver to present preclinical data suggesting its lead drug, (Z)-endoxifen, may address a rare pediatric endocrine disorder called McCune-Albright Syndrome, alongside its core breast-cancer and Duchenne muscular dystrophy programs. The pitch is a single molecule …
Azitra, Inc. (NYSEAMERICAN:AZTR) has told shareholders it is redirecting capital from its slower rare-disease trial toward a cosmetic filaggrin ingredient and licensed recombinant-protein tools, betting on shorter paths to revenue. The shift follows fresh financing, a going-concern warning, two reverse splits and an ongoing …
BioAtla (NASDAQ:BCAB) built its pipeline around Conditionally Active Biologics designed to spare healthy tissue while attacking tumors. In 2026 the San Diego biotech gutted its workforce by roughly 70%, hired an advisor to explore a sale of assets, and disclosed substantial doubt about its …
Please wait processing your request...